sofituzumab vedotin development code monoclonal antibody designed treatment ovarian drug developed genentechroche sofituzumab vedotin antibodydrug conjugate targets protein overexpressed several types cancer including ovarian pancreatic cancer conjugate consists human antibody linked cytotoxic agent mmae released internalization cancer cell addition direct cytotoxic effect sofituzumab vedotin may also mediate antitumor activity signal transduction inhibition antibodydependent cellular cytotoxicity complementdependent cytotoxicity clinical trials shown promising results treatment ovarian pancreatic monoclonal article stub help wikipedia expanding httpsenwikipediaorgwikisofituzumabvedotin